GlassScriptPhysician profile
Richard Rosenthal
NPI 1942295852
$1,820.93
in general payments reported to CMS, 2019-2025
13 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $180 · 2022: $205 · 2023: $15.25 · 2024: $689 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $882.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $476.91 | 2019-2024 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $281.81 | 2019-2024 | Dupixent |
| Optinose US, INC. | $205.72 | 2019-2022 | |
| Alk-Abello, INC | $193.05 | 2019-2020 | |
| Pfizer INC. | $145.60 | 2019-2025 | |
| Genzyme Corporation | $143.31 | 2020-2024 | |
| Blueprint Medicines Corporation | $140.12 | 2024 | Ayvakit |
| Galderma Laboratories, L.P. | $95.30 | 2025 | Nemluvio |
| Takeda Pharmaceuticals U.S.A., INC. | $43.37 | 2022-2024 | Takhzyro |
| Aimmune Therapeutics, INC. | $29.37 | 2022 | |
| Biocryst US Sales Co., LLC | $27.87 | 2025 | Orladeyo |
| Amgen INC. | $22.05 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.45 | 2025 | Xhance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Rosenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.